Revenue segments as reported by the company.

Pharmaceutical

Animal Health

Other Revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Restructuring costs

Other (income) expense, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Merck

Merck & Co., Inc. engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Kenilworth, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Merck reports robust Q4 earnings, eyes growth through innovation

Merck's Q4 2022 performance reflects strong revenue growth and strategic advancements across key therapeutic areas, positioning the company for future success.
While facing challenges such as patent estate concerns and competitive pressures, Merck's focus on innovation and partnerships presents opportunities for sustained growth.
Analyst inquiries and executive responses during the earnings call highlight the company's commitment to transparency, patient outcomes, and shareholder value.

Merck reports robust Q1 earnings, eyes growth in oncology and vaccines

Merck's Q1 performance reflects strong revenue growth driven by oncology and vaccines, with a raised full-year guidance and focus on pipeline advancements.
The company's strategic strengths lie in its focus on compelling science, value alignment in business decisions, and commitment to innovation.
Challenges include potential impacts of EU legislation, post-KEYTRUDA LOE growth strategies, and navigating regulatory complexities for new treatments.
Opportunities in expansion in China, revenue diversification, innovative combination therapies, and protective treatment strategies position Merck for future growth.

Merck reports robust Q2 earnings, focuses on growth opportunities

Merck's Q2 performance showcased strong earnings driven by Oncology and Vaccines growth
Despite challenges like regulatory concerns and price pressures, the company remains focused on innovation
Opportunities lie in expanding KEYTRUDA's reach in cancer indications and advancing in immunology
Overall, Merck's strategic acquisitions and commitment to growth position it well for the future

Merck reports robust Q3 earnings, eyes growth in precision medicine

Merck's Q3 2023 Earnings Call highlighted strong revenue growth, pipeline advancements, and increased full-year revenue guidance. The company's strategic focus on key therapeutic areas and precision medicine approaches positions it for continued success and innovation.

Merck reports robust Q4 earnings, eyes growth through strategic investments

Merck's strong Q4 performance was driven by KEYTRUDA and Vaccines, with positive revenue guidance for 2024. The company remains focused on R&D advancements, strategic investments, and shareholder value. Challenges include managing expenses and maximizing market opportunities.

Merck reports robust Q1 earnings, eyes growth in innovative treatments

Merck's Q1 performance reflects strong revenue growth, operational efficiency, and a positive outlook for future earnings.
The company's focus on innovation, strategic investments, and commitment to patient access position it well for long-term success.
Challenges in pipeline differentiation and market competition require continued strategic planning and differentiation strategies.
Opportunities in new treatment areas, market expansion, and upcoming events offer avenues for sustained growth and market leadership.

Merck reports robust Q2 earnings, eyes future drug launches

Merck's Q2 earnings call highlighted strong financial performance, innovative product launches, and confidence in future growth. The company addressed analyst inquiries, emphasizing long-term pipeline growth and short-term financial guidance while expressing gratitude for investor support.

Merck reports solid Q3 earnings, eyes growth through diversification

Merck's Q3 2024 performance reflects revenue growth driven by key products and clinical advancements, despite regional sales variations and inventory challenges.
The company's strengths in diversification, clinical progress, and strategic investments position it well for future growth and competitive edge in the market.
While facing challenges in specific product sales and clinical trials, Merck has opportunities to capitalize on its strengths, expand offerings, and drive sustained growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Apple

Aehr Test Systems

Codexis

Celsius Holdings

Cisco Systems

Chevron

Enphase Energy

Intrepid Potash

Microsoft

Trillium Therapeutics

Verizon

Walmart

Verizon Communications Inc 5.9 % Notes 2014-15.2.54 Sr

Two sample Breakout Stocks for Week 52 with better than 10% short-term upside potential and a Dow stock pick. This past week, two stocks beat 10% peak gains in FLGT +19.1% and DYAI +13.8% with Momentum Gauge® values improving through the week.

Week 52 MDA Breakout Stocks - December 2021: Short-Term Picks To Give You An Edge

Merck's (MRK) oral antiviral molnupiravir secures the FDA-authorized emergency use tag in treating mild-to-moderate COVID-19 in adults for whom other FDA-approved COVID treatments are unsuitable.

Merck's (MRK) COVID Pill Gets FDA Nod for Emergency Use

Merck and Co Inc announced that its Molnupiravir antiviral pill has been authorised for emergency use by the US Food and Drug Administration (FDA) for treating high-risk adults with mild to moderate coronavirus (COVID-19). The drug has been shown in clinical trials to reduce hospitalisations and deaths by around 30%.

Merck's COVID-19 pill authorised for emergency use by US FDA

Pfizer's COVID-19 antiviral pill will already have some competition in the US: The Food and Drug Administration has given emergency use authorization for Merck's Molnupiravir pill.

Merck's COVID-19 antiviral pill is the second authorized by the FDA

A second pill has been authorized for treating COVID-19.

FDA authorizes Merck pill molnupiravir to treat COVID-19

KENILWORTH, N.J. & MIAMI--(BUSINESS WIRE)---- $MRK #MRK--Merck and Ridgeback's Molnupiravir Receives U.S. FDA Emergency Use Authorization for the Treatment of High-Risk Adults With Mild to Moderate COVID-19

Merck and Ridgeback's Molnupiravir Receives U.S. FDA Emergency Use Authorization for the Treatment of High-Risk Adults With Mild to Moderate COVID-19

Merck's antiviral pill is 30% effective at preventing hospitalizations.

FDA Approves Merck's Antiviral Pill For Emergency Use

The U.S. Food and Drug Administration authorized Merck's COVID-19 antiviral for adults who have tested positive for the virus and are at high risk of disease progression early Thursday, granting it a more limited use than the rival one from Pfizer that was authorized on Wednesday.

Coronavirus Update: FDA adds Merck antiviral to COVID-19 tool kit for high-risk adults above 18, amid flurry of positive news on boosters

Shares of Merck & Co. Inc. MRK, -0.13% were down 0.8% in trading on Thursday after the Food and Drug Administration authorized the company's COVID-19 antiviral for adults who have tested positive for the virus and are at high risk of disease progression. The other caveat of the FDA's authorization for this pill is that it should only be given "when alternative COVID-19 treatment options authorized by the FDA are not accessible or clinically appropriate.

FDA authorizes Merck's COVID-19 antiviral but only when other treatments are 'not accessible' or 'appropriate'

The FDA has approved Merck & Co Inc's (NYSE: MRK) molnupiravir to treat mild-to-moderate COVID-19 in adults. Molnupiravir is not authorized for use in patients younger than 18 years of age because molnupiravir may affect bone and cartilage growth.

FDA Approves Another COVID-19 Antiviral Pill, This Time From Merck

In the latest trading session, Merck (MRK) closed at $76.16, marking a +0.82% move from the previous day.

Merck (MRK) Gains But Lags Market: What You Should Know

The drug proved just 30% effective at preventing hospitalization and death among high-risk patients.

France Cancels Order For Merck's Anti-Covid Pill After Disappointing Trial Results

Pfizer

The FDA is set to authorize COVID-19 treatment pills from Pfizer Inc (NYSE: PFE) and Merck & Co Inc (NYSE: MRK) as early as Wednesday, Bloomberg reported, citing people familiar with the matter. The two drugs, especially Pfizer's pill Paxlovid, are seen as promising new oral treatments that can be taken upon onset of symptoms at home to help prevent COVID-19 hospitalizations and deaths.

FDA To Possibly Authorize Pfizer, Merck COVID-19 Antiviral Pills This Week: Bloomberg

The U.K. government will buy more COVID-19 antiviral pills from Pfizer Inc (NYSE: PFE) and Merck & Co Inc (NYSE: MRK) as it seeks to combat the surge in omicron infections. Britain has secured an additional 1.75 million courses of Merck's drug, molnupiravir, and another 2.5 million courses of Pfizer's paxlovid.

UK Calls For Additional Doses Of COVID-19 Antivirals From Merck, Pfizer

Merck MRK, -1.14% and privately held Ridgeback Biotherapeutics said Wednesday the UK government has ordered an additional 1.75 million courses of their COVID-19 antiviral molnupiravir. The new order brings the total ordered by the UK government o 2.23 million courses.

Merck and Ridgeback Biotherapeutics say UK government has ordered additional 1.75 million doses of their COVID antiviral

KENILWORTH, N.J. & MIAMI--(BUSINESS WIRE)---- $MRK #MRK--Merck and Ridgeback Announce U.K. Government to Purchase Additional 1.75 Million Courses of Molnupiravir

Merck and Ridgeback Announce U.K. Government to Purchase Additional 1.75 Million Courses of Molnupiravir

Morgan Stanley

Target

Are defensive stocks the best way to navigate the current market conditions?

Best Defensive Stocks To Invest In Late 2021? 3 For Your List

DARMSTADT, Germany--(BUSINESS WIRE)--Merck, a leading science and technology company, today announced a strategically focused expansion of its neurology pipeline with the acquisition of the rights to develop cladribine for the treatment of generalized myasthenia gravis (gMG) and neuromyelitis optica spectrum disorder (NMOSD). Merck entered into an agreement to secure the global rights by acquiring Chord Therapeutics, a Swiss-based biotech company focused on rare neuroinflammatory diseases. “Cla

Merck Expands Neuroinflammatory Pipeline with Acquisition of Chord Therapeutics

Regeneron Pharmaceuticals

Our indicative theme on Covid-19 Treatment Stocks – which includes biotech and pharma companies selling or developing treatments for the Covid-19 virus – is up by 25% year-to-date, compared to the S&P 500 which is up about 26% over the same period. Although we were somewhat circumspect about the.

Pfizer, Merck, Regeneron: Covid Treatment Stocks Back In Focus As Infections Soar

LUND, SE / ACCESSWIRE / December 17, 2021 / BioInvent International (STO:BINV) Partial response in metastatic uveal melanoma, a difficult-to-treat indication Markedly improvement of stage IV sarcoma BioInvent International AB ("BioInvent") (Nasdaq Stockholm: BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, announces positive early data from the ongoing clinical study of its novel anti-FcyRIIB antibody BI-1206 in combination with anti-PD-1 therapy pembrolizumab (Keytruda®) for the treatment of patients with solid tumors. Early observations are that BI-1206 may stem and reverse metastatic disease progression in patients who have previously progressed on PD-1/PDL-1 therapies and other prior treatments.

BioInvent announces positive early data from ongoing solid cancer trial of BI-1206 in combination with pembrolizumab

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending approval for Merck & Co Inc's  (NYSE: MRK) Keytruda for renal cell carcinoma (RCC). The opinion covers Keytruda as monotherapy for the adjuvant treatment of RCC patients at increased risk of recurrence following nephrectomy or resection of metastatic lesions.

EMA's CHMP Backs Approval For Merck's Keytruda In Adjuvant Setting For Kidney Cancer

The EU drug regulator might not decide whether to approve Merck & Co Inc's (NYSE: MRK) molnupiravir, COVID-19 antiviral until after Christmas, a source with knowledge of the matter said, Reuters said. But according to the source, the European Medicines Agency (EMA) may rule before Christmas whether to give Gilead Sciences Inc's (NASDAQ: GILD) intravenous antiviral drug Remdesivir full marketing approval.

EMA Might Not Decide On Merck's COVID-91 Oral Antiviral Before Christmas: Reuters

It's too soon to know for sure what might happen with Merck's islatravir.

Why This Once-Promising HIV Candidate Could Be in Trouble

Merck is going after Pfizer's COVID-19 pill even before the drug is on the market.

Is Merck's Dig at Pfizer's COVID-19 Pill Justified?

KENILWORTH, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck Receives Positive EU CHMP Opinion for KEYTRUDA® as Adjuvant Therapy for Certain Patients With Renal Cell Carcinoma Following Surgery

Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) as Adjuvant Therapy for Certain Patients With Renal Cell Carcinoma Following Surgery

News for Merck Stock (MRK)